Yttrium News and Research

RSS
Yttrium is a metal of the rare earth group of elements. A radioactive form of yttrium may be attached to a monoclonal antibody or other molecule that can locate and bind to cancer cells and be used to diagnose or treat some types of cancer.
Researchers report first experimental evidence that supports theory of buckyball

Researchers report first experimental evidence that supports theory of buckyball

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Countrywide study in Germany deems PRRT as life-prolonging treatment for patients with NETs

Countrywide study in Germany deems PRRT as life-prolonging treatment for patients with NETs

Novel way to design metal organic frameworks under completely liquid-free conditions

Novel way to design metal organic frameworks under completely liquid-free conditions

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Nordion announces additional TheraSphere Phase III trial for HCC

Nordion announces additional TheraSphere Phase III trial for HCC

Spectrum signs definitive agreement to acquire Allos

Spectrum signs definitive agreement to acquire Allos

Nordion introduces new custom dose feature in Canada, Europe for TheraSphere

Nordion introduces new custom dose feature in Canada, Europe for TheraSphere

Nordion celebrates first anniversary of market launch of TheraSphere

Nordion celebrates first anniversary of market launch of TheraSphere

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

Enrollment opens in sorafenib vs. radioembolization in advanced hepatocellular carcinoma trial

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Advances in yttrium-90 radioembolization for liver cancer

Advances in yttrium-90 radioembolization for liver cancer

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Theorem Clinical Research receives contract to conduct Nordion's TheraSphere Phase III trials

Theorem Clinical Research receives contract to conduct Nordion's TheraSphere Phase III trials

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

Cancer Centers of North Carolina buys WROS from Wake Radiology

Cancer Centers of North Carolina buys WROS from Wake Radiology

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting